Status:
COMPLETED
Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease
Lead Sponsor:
Institute for Neurodegenerative Disorders
Collaborating Sponsors:
United States Department of Defense
Conditions:
Parkinson Disease
Eligibility:
All Genders
30+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to investigate the utility of dopamine transporter imaging in monitoring and predicting the progression of Parkinson disease. This study will be performed in the PRECEPT c...
Detailed Description
The 800 early PD subjects in this study have already been evaluated clinically and have undergone longitudinal dopamine transporter (DAT) imaging with \[123I\] ß-CIT (baseline and 22 months). In Follo...
Eligibility Criteria
Inclusion
- Subject was a participant in the PRECEPT clinical and imaging study
- Participant must be willing and able to comply with study procedures
- Participant must be willing and able to give informed consent.
Exclusion
- The participant has a clinically significant clinical laboratory value and/or medical or psychiatric illness
- The participant has dementia (MMSE≤24)
- Pregnancy
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2014
Estimated Enrollment :
396 Patients enrolled
Trial Details
Trial ID
NCT00404170
Start Date
November 1 2006
End Date
July 1 2014
Last Update
July 5 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute for Neurodegenerative Disorders
New Haven, Connecticut, United States, 06510